Recipharm AB, a contract development and manufacturing organization (CDMO) based in Jordboro, Sweden, has completed the purchase of the Flamel Technologies SA facility located in Pessac, France.

The companies plan to integrate the facility into its operations, which further include two acquisitions of Recipharm made in 2014: Corvette Pharmaceutical Services Group, a Milan, Italy-headquartered CDMO, and Lusomedicamenta, a CDMO based in Lisbon, Portugal.

Corvette had 2013 revenue of EUR 57.7 million ($76.8 million). Forty percent of its sales are to Italy, and 20% of its sales are to emerging markets. Corvette has three manufacturing facilities located in the Milan region of Northern Italy. Each facility specializes in a different technology and business area. In Masate, the company has a sterile injectable manufacturing facility with capabilities for both lyophilization and liquid filling of vials and ampuls, including hormones supplied to numerous territories, including Japan. At Paderno Dugnano, the company has an active pharmaceutical ingredient and finished dose form development and manufacturing facility with a number of owned product rights, including Erdosteine, a mucolytic product. The facility supplies the global market, including the US and Japan. The company’s facility in Lainate provides bulk lyophilization of sterile beta-lactam antibiotics supplied to numerous markets, including Japan. Approximately 265 people are employed across the three facilities. Recipharm has manufacturing assets in Sweden, France, the UK, Germany, and Spain. The deal addresses current and short-term capacity shortages for Recipharm as it waits for new capacity to come on stream in its existing facility. The deal also provides Recipharm with the capability of handling hormones in both vials and ampules.

Lusomedicamenta is primarily a CDMO specialized in the development and manufacture of solid, liquid and semisolid dose forms as well as sterile ophthalmic products. It operates from two sites located close to Lisbon and has invested heavily in the production of effervescent tablets with anew dedicated facility for this purpose. The company is also focused on new products carrying the management of the whole process from product development to the registration dossier. Lusomedicamenta employs around 340 people and produces over 150 formulations in more than 600 SKUs, exporting to some 45 countries worldwide.

Source: Recipharm